PLAU and severe combined immunodeficiency: The increased antiviral functions of IFNα-NKs were also observed in vivo using the humanized chimeric urokinase-type plasminogen activator/severe combined immunodeficiency (uPA/SCID) mouse model, which supports the whole HCV biological cycle [19].